Biomarker-based precision dose finding for immunotherapy combined with radiotherapy

DOI10.1002/BIMJ.202200246MaRDI QIDQ6572286zbMATH OpenFDO

Authors Yan Han, Rui Zhang, Beibei Guo

Publication date 15 July 2024

Published in Biometrical Journal (Search for Journal in Brave)

zbMATH Keywords

radiotherapyimmunotherapybiomarkersdose findingBayesian adaptive designpatient subgroupsimmunoRTPD-L1 expression

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A Bayesian phase I/II trial design for immunotherapy
• A weakly informative default prior distribution for logistic and other regression models
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times
• Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
• Robust EM continual reassessment method in oncology dose finding
• Sampling-Based Approaches to Calculating Marginal Densities
• Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points

This page was built for publication: Biomarker-based precision dose finding for immunotherapy combined with radiotherapy

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6572286)